CliffBio

Supernus Pharmaceuticals

Patent cliffs & loss of exclusivity

Small Molecules

Company

CAGE Code6WHD6
Legal NameSupernus Pharmaceuticals, Inc.
Company Operating StatusActive
Contact Page URLhttps://www.supernus.com/contact-us
Crunchbase URLhttps://www.crunchbase.com/organization/supernus-pharmaceuticals
Full Address9715 Key West Ave, Rockville, Maryland 20850, US
LinkedIn URLhttps://www.linkedin.com/company/supernus-pharmaceuticals/
Pitchbook URLhttps://pitchbook.com/profiles/company/51347-08

16 upcoming patent cliffs

DrugIngredientTypeCliff
  1. OXTELLAR XROXCARBAZEPINESmall mol.Apr 2027
  2. OXTELLAR XROXCARBAZEPINESmall mol.Apr 2027
  3. OXTELLAR XROXCARBAZEPINESmall mol.Apr 2027
  4. TROKENDI XRTOPIRAMATESmall mol.Apr 2028
  5. TROKENDI XRTOPIRAMATESmall mol.Apr 2028
  6. TROKENDI XRTOPIRAMATESmall mol.Apr 2028
  7. TROKENDI XRTOPIRAMATESmall mol.Apr 2028
  8. QELBREEVILOXAZINE HYDROCHLORIDESmall mol.Apr 2035
  9. QELBREEVILOXAZINE HYDROCHLORIDESmall mol.Apr 2035
  10. QELBREEVILOXAZINE HYDROCHLORIDESmall mol.Apr 2035
  11. OSMOLEX ERAMANTADINE HYDROCHLORIDESmall mol.Feb 2038
  12. OSMOLEX ERAMANTADINE HYDROCHLORIDESmall mol.Feb 2038
  13. OSMOLEX ERAMANTADINE HYDROCHLORIDESmall mol.Feb 2038
  14. OSMOLEX ERAMANTADINE HYDROCHLORIDESmall mol.Feb 2038
  15. GOCOVRIAMANTADINE HYDROCHLORIDESmall mol.Aug 2038
  16. GOCOVRIAMANTADINE HYDROCHLORIDESmall mol.Aug 2038

Loss-of-exclusivity dates are derived from the FDA Orange & Purple Books; company detail is from the CliffBio graph. Estimates are projections, not legal advice.

Supernus Pharmaceuticals — patent cliffs & loss of exclusivity | CliffBio